These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20606412)

  • 1. Can we use EBV-DNA monitoring to predict disease relapse in EBV-positive hodgkin lymphoma patients?
    Spacek M; Hubacek P; Markova J; Zajac M; Vernerova Z; Kozak T
    Acta Haematol; 2010; 124(1):23-6. PubMed ID: 20606412
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
    Gandhi MK; Lambley E; Burrows J; Dua U; Elliott S; Shaw PJ; Prince HM; Wolf M; Clarke K; Underhill C; Mills T; Mollee P; Gill D; Marlton P; Seymour JF; Khanna R
    Clin Cancer Res; 2006 Jan; 12(2):460-4. PubMed ID: 16428487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma.
    Hohaus S; Santangelo R; Giachelia M; Vannata B; Massini G; Cuccaro A; Martini M; Cesarini V; Cenci T; D'Alo F; Voso MT; Fadda G; Leone G; Larocca LM
    Clin Cancer Res; 2011 May; 17(9):2885-92. PubMed ID: 21478335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sequential monitoring of plasma EBV-DNA level in a patient with EBV-positive Hodgkin lymphoma].
    Uchida E; Honma R; Igarashi A; Kurata M; Imadome K; Omoto E; Miura O; Arai A
    Rinsho Ketsueki; 2012 Jan; 53(1):87-91. PubMed ID: 22374530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of whole blood Epstein-Barr virus DNA is useful for assessing treatment response in patients with non-Hodgkin's lymphoma.
    Jo SA; Hwang SH; Kim SY; Shin HJ; Chung JS; Sol MY; Chang CL; Lee EY
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e106-13. PubMed ID: 19522857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.
    Diepstra A; van Imhoff GW; Schaapveld M; Karim-Kos H; van den Berg A; Vellenga E; Poppema S
    J Clin Oncol; 2009 Aug; 27(23):3815-21. PubMed ID: 19470931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma.
    Van Baarle D; Wolthers KC; Hovenkamp E; Niesters HG; Osterhaus AD; Miedema F; Van Oers MH
    J Infect Dis; 2002 Aug; 186(3):405-9. PubMed ID: 12134237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin's lymphoma.
    Lacroix A; Jaccard A; Rouzioux C; Piguet C; Petit B; Bordessoule D; Ranger-Rogez S
    J Med Virol; 2007 Sep; 79(9):1349-56. PubMed ID: 17607791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of Epstein-Barr virus DNA and RNA in tissues of patients with lymphoma].
    Zeytinoğlu A; Hekimgil M; Erensoy S; Aydemir S; Berber S; Cağirgan S; Soydan S; Bilgiç A
    Mikrobiyol Bul; 2005 Oct; 39(4):473-81. PubMed ID: 16544549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.
    Sirvent-Von Bueltzingsloewen A; Morand P; Buisson M; Souillet G; Chambost H; Bosson JL; Bordigoni P
    Bone Marrow Transplant; 2002 Jan; 29(1):21-8. PubMed ID: 11840140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients.
    Chan KC; Zhang J; Chan AT; Lei KI; Leung SF; Chan LY; Chow KC; Lo YM
    Cancer Res; 2003 May; 63(9):2028-32. PubMed ID: 12727814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease.
    Delecluse HJ; Marafioti T; Hummel M; Dallenbach F; Anagnostopoulos I; Stein H
    J Pathol; 1997 Aug; 182(4):475-9. PubMed ID: 9306970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection.
    Bauer CC; Aberle SW; Popow-Kraupp T; Kapitan M; Hofmann H; Puchhammer-Stöckl E
    J Med Virol; 2005 Jan; 75(1):54-8. PubMed ID: 15543583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma.
    Chang ET; Zheng T; Lennette ET; Weir EG; Borowitz M; Mann RB; Spiegelman D; Mueller NE
    J Infect Dis; 2004 Jun; 189(12):2271-81. PubMed ID: 15181575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma.
    Ishii H; Ogino T; Berger C; Köchli-Schmitz N; Nagato T; Takahara M; Nadal D; Harabuchi Y
    J Med Virol; 2007 May; 79(5):562-72. PubMed ID: 17385697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.